Lumida
/SNWV
⌘K
SANUWAVE Health Inc

SANUWAVE Health Inc

SNWV
$6.39USD↓-3.91%-0.26 today

MARKET CAP

54.9M

P/E (TTM)

6.7x

FWD P/E

4.6x

DAY RANGE

$6 – $7

52W RANGE

$6
$47

AI Summary

Stalk
TrimMedium

In a Stage 4 decline, both medium- and long-term biases remain bearish. Despite an extreme oversold bounce, price is still below the downward-sloping 9/21 EMAs without any clear rejection at resistance levels. With no definitive short-side trigger, execution should be deferred, awaiting a pullback into the EMA zone for a structurally sound short entry.

  • ↑Q1 2026 revenue rose to $9.6 M (+3% YoY), the highest Q1 in company history.
  • ↑Management forecasts Q2 sales of $11.1–11.6 M, implying 10–15% YoY growth.
  • ↓Q1 operating loss of $1.1 M contrasts with prior $0.6 M profit.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

SanuWave Holdings, Inc. (NASDAQ: SNWV), operates in the advanced wound care market, specializing in innovative ultrasound-based solutions like the Ultramis system for treating chronic wounds. The company is strategically positioned to capitalize on the increasing demand for effective wound care solutions amidst regulatory changes and a competitive environment. SanuWave aims to enhance clinical outcomes and patient care while expanding its presence in the healthcare sector through strong relationships with hospitals and long-term care facilities.

Bull says

  • ↑Q1 2026 revenue rose to $9.6 M (+3% YoY), the highest Q1 in company history.
  • ↑Management forecasts Q2 sales of $11.1–11.6 M, implying 10–15% YoY growth.
  • ↑Active Ultramis systems climbed to 1,382, signaling rising utilization.
  • ↑Net loss narrowed to $1.4 M from $6.1 M YoY; operating loss improved.
  • ↑Balance sheet strength with minimal debt supports operational flexibility.
  • ↑Undervalued at book-to-price ~1.12; buy-the-dip appeal amid solid patent moat.

Bear says

  • ↓Q1 operating loss of $1.1 M contrasts with prior $0.6 M profit.
  • ↓Analysts are cutting earnings forecasts, reflecting confidence erosion.
  • ↓Negative price momentum and all-time low share at $7.53 deter buyers.
  • ↓Revenue reliant on few large customers risks sharp order swings.
  • ↓Sales tax compliance and disclosure agreements may strain cash flow.
  • ↓Weak earnings yield and small-cap profile signal heightened risk exposure.

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 06-02-2026bullish

Transcript signals

Bull points

  • Q1 was a strong start to the year, coming in ahead of expectations, and obviously we're very pleased to put up a 61% year-on-year growth comp in a quarter in which we hired a new head of sales and worked through some associated Salesforce restructuring.
  • Placing 98 new Ultimis systems in Q1 represented a 128% increase from system sales of 43 in Q1 of last year.
  • the quarter came in a bit stronger than we expected, but you know, never a bad thing to get a good start to the year, especially in Q1, which is typically a quieter time seasonally for Sandy Wave and for medical device in general.

Bear points

  • Just as a note of housekeeping, our uplist to NASDAQ this quarter was a great step for us, but it also came with a $295,000 listing fee, which affected our operating profit, our EBITDA, and our adjusted EBITDA figures.
  • Net loss for the three months ended March 31st, 2025 was $5.7 million compared to a net loss of $4.5 million for the same period in 2024.
  • The increase in net loss was primarily driven by higher non-cash and infrequent expenses, including stock-based compensation expense and changes in the fair value of derivative liabilities, which resulted in a $4.9 million loss this quarter versus $2.5 million in Q1 of 2024.
Read full transcript analysis ›